Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in breastmilk
NCT05978713Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity at 672 hours. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05978713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978713.